Last reviewed · How we verify
NCT05055427
Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients
Phase 2, PHASE3 trial testing Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng) in COVID-19 Respiratory Infection in 300 participants. Completed in 25 December 2021.
25 December 2021
Quick facts
| Lead sponsor | University of Medicine and Pharmacy at Ho Chi Minh City |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 20 August 2021 |
| Primary completion | 25 December 2021 |
| Estimated completion | 25 December 2021 |
| Sites | 1 location across Vietnam |
Drugs / interventions tested
- Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng) — full drug profile →
Conditions studied
- COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →
- Herbal Medicine — all drugs for Herbal Medicine →
Sponsor
University of Medicine and Pharmacy at Ho Chi Minh City
Who can join
Adults 18 to 64, any sex, with COVID-19 Respiratory Infection or Herbal Medicine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19 (coronavirus disease 2019). Patients with COVID-19 may experience various clinical manifestations, from no symptoms to critical illness such as severe pneumonia and acute respiratory distress syndrome (ADRS). So far, there is no specific medication for COVID-19; hence, the current available treatments mostly aim at symptoms management and supportive care. From traditional medicine perspective, COVID-19 is classified as warm-disease (Wen-yi). The main points of treatment for COVID-19 in early stage based on traditional medicine perspective are strengthen the Protective Qi (Wei Qi - the body immune system), and restore the balance of Qi, which is vital biological energy to prevent the invasion of external pathogens, including the SARS-CoV-2 virus. The Shen Cao Gan Jiang Tang have including Gan Cao Gan Jiang Tang (GGT) with the addition of Ginseng. This formula is originated from Shang Han Lun (Treatise on Febrile Diseases Caused by Cold) by Zhang Zhong-jing, used to enhance the Protective Qi, treat the early stage of Febrile Diseases, This clinical trial aims to evaluate the efficacy of the Shen Cao Gan Jiang Tang on mild and moderate COVID-19 patients
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Herbal Remedies, Nutraceuticals, and Dietary Supplements for COVID-19 Management: An Update.
Chavda VP, Patel AB, Vihol D, Vaghasiya DD, et al · · 2022 · cited 29× · PMID 36620357 · DOI 10.1016/j.ccmp.2022.100021 -
Efficacy of Shen Cao Gan Jiang Tang on Non-severe COVID-19 Patients: A Multicenter, Randomized, Open-Label Clinical Trial.
Trinh DT, Tran AH, Bui MP, Kieu TX, et al · · 2024 · PMID 39006557 · DOI 10.7759/cureus.62380
Verify or expand the search:
- PubMed search for NCT05055427
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)
Trials testing the same drug.
- NCT05228873 — Comparison of Quality of Life After Discharge of the Mild and Moderate COVID-19 Patients With or Without Herbal Medicine · completed
Other recruiting trials for COVID-19 Respiratory Infection
Currently open trials in the same condition.
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT05689034 — Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 · Phase 2, PHASE3 · recruiting
- NCT05562505 — Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure · NA · recruiting
Other University of Medicine and Pharmacy at Ho Chi Minh City trials
Trials by the same sponsor.
- NCT07530042 — Efficacy of Electroacupuncture Combined With Auricular Acupressure for Chronic Low Back Pain. · NA · not yet recruiting
- NCT07537439 — Evaluation of the Adjunctive Effects of Moxibustion in the Treatment of Cold-Syndrome Allergic Rhinitis · NA · not yet recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT07520071 — "Xuong Tan Lac Than" Exercise for Range of Motion and Muscle Endurance · NA · recruiting
- NCT07487181 — A Survey of Traditional Medicine Pattern Identification in Patients With Erectile Dysfunction · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05055427 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Medicine and Pharmacy at Ho Chi Minh City
- Last refreshed: 31 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05055427.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing